ArticlePharmacoEconomics2022
Findings from a Roundtable Discussion with US Stakeholders on Valuation of the EQ-5D-Y-3L.
Article in PharmacoEconomics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- The Influence of Perspective on the Valuation of the EQ-5D-Y-3L: A Comparison Using the OPUF Tool and a Discrete Choice Experiment.PharmacoEconomics · 2026Trial
- Justifying and Classifying Adults' Roles in Child Health State Valuation: A Novel Taxonomy.PharmacoEconomics · 2026Review
- The EQ-5D-5L valuation study in Nigeria.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2026Article
- Nothing about us, without us? A reflection on and call for involving children in the process of valuing child health.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- EQ-5D(-Y) Valuation from Adult and Child Perspectives: Where Does the Empirical Evidence Leave Us and How Should We Proceed?PharmacoEconomics · 2026Review
- Improving Collaborative Engagement in Health State Valuation: A Scoping Review of Current Practices and Emerging Recommendations.PharmacoEconomics · 2026Review
- Exploring valuation of a modified EQ-5D-Y-3L adapted for 2-4 year olds: a think-aloud study.Health and quality of life outcomes · 2025Article
- Eliciting and Anchoring Health State Preferences Using Discrete Choice Experiments Among Adults, Adolescents, and Children.PharmacoEconomics · 2025Article
- Measuring and Valuing Health Using EuroQol Instruments: New Developments 2025 and Beyond.Applied health economics and health policy · 2025Review
- An Australian Value Set for the EQ-5D-Y-3L.Health and quality of life outcomes · 2025Article
- Findings from a roundtable discussion with Pakistani stakeholders on measuring and valuing health and health-related quality of life for children and adolescents.Health and quality of life outcomes · 2025Article
- A Taxonomy for Assessing Whether HRQoL Value Sets Are Obsolete.PharmacoEconomics · 2025Article
- Article
- Understanding Canadian stakeholders' views on measuring and valuing health for children and adolescents: a qualitative study.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2024Article
- EQ-5D-Y-3L Value Sets, Valuation Methods and Conceptual Questions.PharmacoEconomics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe International Valuation Protocol for the valuation of the EQ-5D-Y-3L provides baseline guidance, but country-specific context is also important. This study aimed to obtain US stakeholders' input on key considerations for youth valuation in the US.
methodsA total of 14 stakeholders representing various backgrounds were identified via the investigators' networks. A 2-h online meeting was held to discuss (1) the need for a US value set for the EQ-5D-Y-3L; (2) willingness to pay more for quality-adjusted life-year (QALY) gains for children versus adults; (3) sampling strategies; (4) framing perspectives; and (5) other challenges. The session was recorded, transcribed, and summarized.
resultsSeveral stakeholders supported paying more for QALY gains for children in recognition of their potential future contributions to society, as well as to avoid potential undervaluation and promote access to innovative treatments. Concerns regarding possible double counting, lack of data to showcase long-term benefits, and dangers of paying more for certain subgroups were also expressed. Most of the stakeholders felt that adolescents could relate to a 10-year-old's perspective better than adults and were capable of self-completing valuation tasks, and thus should be directly included in the valuation study. There were concerns that adults would be inconsistent in their views about a 10-year-old, partly depending on their status as a parent.
conclusionsUS stakeholders provided insights relevant to youth valuation in a US context and were open to continued dialogue with investigators. This study could be useful to investigators who are conducting youth valuation studies in different countries and seeking stakeholder input.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.